Adenocarcinoma of the Esophagus Clinical Trial
Official title:
AdCa of the Esophagus and Cardia (ADEC): Relationship Between Nodal Metastasization and the Presence Absence of Intestinal Metaplasia in the Esophagus and Stomach
Adenocarcinoma of the distal esophagus and cardia are grouped among the thoracic tumors according to the TNM 7th ed., however controversy is pending on the unique or dual pathogenesis (GERD or gastric-like cancerogenesis). It has been shown that biological patterns differ according to the presence (+) or absence (-) of Barrett's epithelium (BIM) and gastric intestinal metaplasia (GIM) in the fundus and antrum. Lymphatic metastatic spreading may differ according to the type of tumor. The investigators retrospectively investigated the pathways of lymphatic spreading in 194 consecutive patients who received radical surgery for adenocarcinoma of the esophagus and cardia with or without BIM and GIM.
The assumption that adenocarcinoma of the esophagus and cardia (ADEC) originates only from
the sequence intestinal metaplasia followed by dysplasia and cancer is controversial. It has
been shown that biological patterns differ according to the presence (+) absence (-) of
Barrett's epithelium (BIM) and of gastric intestinal metaplasia (GIM) in the fundus and
antrum. Lymphatic metastatic spreading may differ according to the type of tumor.
Preoperatively patients underwent histological search for Barrett's esophagus (BIM) in
mucosa surrounding (ADEC) and intestinal metaplasia in the gastric corpus and antrum mucosa
(GIM). Patients in which BIM was documented underwent sub total esophagectomy and gastric
pull up (group 1), others underwent esophagectomy at the azygos vein + total gastrectomy
with Roux Y esophagojejunostomy (group 2). Radical lymphadenectomy was identical in both
procedures except for the greater curvature station.
;
Observational Model: Cohort, Time Perspective: Retrospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00098527 -
FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
|
Phase 2 | |
Completed |
NCT01612546 -
Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
|
Phase 2 | |
Terminated |
NCT00003487 -
Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus
|
Phase 2 | |
Withdrawn |
NCT02344810 -
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00061958 -
Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 2 | |
Terminated |
NCT00064259 -
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00045526 -
Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer
|
Phase 2 | |
Completed |
NCT01129206 -
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
|
Phase 2 | |
Withdrawn |
NCT03307941 -
Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06161818 -
Total Neoadjuvant Therapy for Adenocarcinoma of the OESophagus and Oesophagogastric Junction: TNT-OES-2 Trial
|
Phase 2 | |
Terminated |
NCT00573131 -
Efficacy and Safety of OncoGelâ„¢ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
|
Phase 2 | |
Completed |
NCT00077545 -
3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction
|
Phase 2 | |
Completed |
NCT01231399 -
Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02037048 -
FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma
|
Phase 2 | |
Terminated |
NCT01395537 -
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
|
Phase 1/Phase 2 | |
Completed |
NCT01212822 -
Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
|
Phase 2 | |
Completed |
NCT01561014 -
Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
|
Phase 1 |